Jim joins Maverick from MacroGenics, Inc. (Nasdaq: MGNX), where as Vice President of Clinical Research since 2014, he developed clinical strategy and oversaw execution of Phase 1 / 2 studies for multiple immuno-oncology assets. Prior to MacroGenics, Jim spent 9 years at AstraZeneca / MedImmune, leading Phase 1 / 2 studies with the anti-PD-L1, durvalumab. While at AstraZeneca Jim led the Phase 2 and pivotal Phase 3 study of vandetanib in thyroid cancer, and then had leading roles in gaining FDA and EMA approval for vandetanib. Jim worked at the NCI from 1995 to 2005, initially as a Surgical Oncology and Clinical Trial Research Fellow in the Surgery Branch under Dr. Steven Rosenberg. He then worked under Drs. Richard Klausner and Marston Linehan as a Basic Science Research Fellow in the NCI Urology Branch.
Jim earned a B.A. in Engineering from Lafayette College, an M.D. from New York Medical College, and completed a General Surgical Residency at Morristown Memorial Hospital.